Sherman Biotech Plans Studies and Clinical Trials for Treatment of Anxiety Associated With Fragile X Syndrome, Autism.Early Detect Inc. Subsidiary Schedules Seminars in Chicago, Boston and New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of to Discuss Plans to Bring New Anxiety Therapy to Market CHICAGO -- Sherman Biotech Inc., a wholly-owned subsidiary of Early Detect, Inc., announced today that it has scheduled seminars this fall in Chicago, Boston and New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. to discuss the company's plans to begin preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. and clinical trials of SB15, a newly-formulated compound for the treatment of anxiety associated with fragile X syndrome Fragile X Syndrome Definition Fragile X syndrome is the most common form of inherited mental retardation. Individuals with this condition have developmental delay, variable levels of mental retardation, and behavioral and emotional difficulties. and autism autism (ô`tĭzəm), developmental disability resulting from a neurological disorder that affects the normal functioning of the brain. It is characterized by the abnormal development of communication skills, social skills, and reasoning. . SB15 shows promise as an alternative to current drug therapies, such as stimulants, antidepressants Antidepressants Medications prescribed to relieve major depression. Classes of antidepressants include selective serotonin reuptake inhibitors (fluoxetine/Prozac, sertraline/Zoloft), tricyclics (amitriptyline/ Elavil), MAOIs (phenelzine/Nardil), and heterocyclics and anticonvulsants Anticonvulsants Drugs used to control seizures, such as in epilepsy. Mentioned in: Antipsychotic Drugs, Osteoporosis that broadly suppress anxiety in individuals with these conditions. "Our research shows that the formulated version of SB15 could have therapeutic benefits for anxiety in appropriate patients," said Dr. David Schwartz David Schwartz is a composer, noted for his scoring the music for the multiple Emmy Award-winning television series, Arrested Development, Deadwood, and numerous others. He attended the School of Visual Arts in New York and the Berklee College of Music in Boston. , Sherman Biotech's chief science officer. Charles Strongo, Early Detect's chief executive officer, states, "Early Detect and its subsidiaries are committed to finding more effective treatments for such serious conditions as autism and Fragile X. Autism is clearly on the rise around the world, and anyone who has been touched by this disability understands the difficulties associated with finding effective treatment therapies." At the seminars, Early Detect and Sherman Biotech executives will discuss preliminary animal studies that indicate SB15 has only mild side effects Side effects Effects of a proposed project on other parts of the firm. and is highly effective as a potential treatment. They will also discuss the company's plans to finance the development of the therapy as a candidate through preclinical toxicity studies, followed by human clinical trials. All interested parties are encouraged to attend the informational seminars. For the details of locations and times, call Kevin Miller For other persons of the same name, see Kevin Miller (disambiguation). Kevin Miller (born 1968) is a conservative American talk radio host and political pundit who has been featured on many national news programs, including The Today Show, Leeza Gibbons, CNN, and MSNBC. at 517-482-3624. About Sherman Biotech Inc. Sherman Biotech Inc. is an early-stage company specializing in the development of pharmaceutical compounds for the specific treatment of anxiety in the inherited disorder known as fragile X and in related conditions such as autism. Sherman Biotech is also conducting research to create diagnostic tests for these conditions. About Early Detect Inc. Early Detect, Inc., was founded in 1996 with the mission of empowering individuals to take control of their health and healthcare. The only company to have a single-branded, comprehensive line of home health test kits, Early Detect is committed to providing safe and effective health tests for both consumers and the medical community. Early Detect and its subsidiaries, Sherman Biotech and PanProbe, strive to develop and successfully market treatments and detection tests that improve overall health and well-being. This release has been prepared solely for the information of the recipient, and may not be used for any other purpose. Some of the statements in this release may constitute forward-looking statements, since such statements relate to matters which have not yet occurred, and have been prepared on the basis of assumptions and hypotheses deemed appropriate by the companies. Future operating results are impossible to predict and no representations can be or are being made with respect to the future accuracy or completeness of any forecasts or projections. This release does not constitute an offer or solicitation for the sale or purchase of securities. Any offering for the sale or purchase of securities involves a high degree of risk. Potential investors are expected to make their own investigation and to consult with their own advisors and counsel as to the consequences of an investment. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion